Multiple organ support therapy for the critically ill patient in intensive care

Journal of Organ Dysfunction

Volumn 1, Issue 1, 2005, Pages 57-68

  Ronco, Claudio ^a   Ratanarat, Ranistha ^a   Bellomo, Rihaloo ^b   Salvatori, Gabriella ^a   Petras, Dimitri ^a   Cal, Massimo de ^a   Nalasso, Federico ^a   Bonello, Monica ^a   Brendolan, Alessandra ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

CRRT; extracorpozeal therapy; multiple organ failure

Indexed keywords

EID: 33646565107     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.1080/17471060500233109     Document Type: Article

References (101)

1. Cosentino F, Chaff C, Piedmonte M. Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 1994; 9 (Suppl 4) 179–182
2. Liano G, Pascual J. Acute renal failure. Madrid Acute Renal Failure Study Group. Lancet 1996; 347: 479
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–1655
4. Camussi G, Montrucchio G, Dominioni L, Dionigi R. Septic shock – the unravelling of molecular mechanisms. Nephrol Dial Transplant 1995; 10: 1808–1813
5. Bellomo R, Ronco C. Indications and criteria for initiating renal replacement therapy in the intensive care unit. Kidney Int 1998; 53 (Suppl 66) S106–S109
6. Kellum JA, Venkataraman R. Application of blood purification to non-renal organ failure. Int J Artif Organs 2005; 28: 445–449
7. Bellomo R, Honore PM, Matson J, Ronco C, Winchester J. Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 2005; 28: 450–458
8. Bellomo R, Ronco C. The changing pattern of acute renal failure. Nephrology 1996; 2: 149–154
9. Bellomo R, Mehta R. Acute renal replacement in intensive care medicine: now and tomorrow. New Horiz 1995; 3: 760–767
10. Canaud B, Mion C. Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Adv Nephrol 1995; 24: 271–281
11. Brendolan A, D'Intini V, Ricci Z, Bonello M, Ratanarat R, Salvatori G, et al. Pulse high volume hemofiltration. Int J Artif Organs 2004; 27: 398–403
12. Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z, Ronco C. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 2005; 9: R294–R302
13. Uchino S, Bellomo R, Ronco C. Intermittent vs. continuous renal replacement in the ICU: impact on sodium, potassium, and bicarbonate concentrations. Intensive Care Med 2001; 27: 1037–1043
14. Tan HK, Bellomo R, M'pisi DA, Ronco C. Phosphatemic control during acute renal failure: intermittent hemodialysis vs. continuous hemodiafiltration. Int J Artif Organs 2001; 24: 186–191
15. Tan HK, Bellomo R, M'pisi DA, Ronco C. Ionized serum calcium levels during acute renal failure: intermittent hemodialysis vs. continuous hemodiafiltration. Ren Fail 2002; 24: 19–27
16. Bellomo R, Raman J, Ronco C. Intensive care management of the critically ill patient with fluid overload after open heart surgery. Cardiology 2001; 96: 169–176
17. Heulitt MJ, Marshall J. Kidney function during extracorporeal lung assist techniques (ECMO/ECCO2R). Critical care nephrology, C Ronco, R Bellomo. Kluwer Academic, Dordrecht 1998; 1073–1079
18. Ronco C, Bellomo R, Brendolan A, Pinna V, La Greca G. Brain density changes during renal replacement therapy in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. J Nephrol 1999; 12: 173–178
19. Moe SM, Sprague SM. Uremic encephalopathy. Clin Nephrol 1994; 42: 251–256
20. Bellomo R, Tan HK, Bhonagiri S, Gopal I, Seacombe J, Daskalakis M, Boyce N. High protein intake during continuous hemodiafiltration: impact on amino acids and nitrogen balance. Int J Artif Organs 2002; 25: 261–268
21. Guisado R, Arieff AI. Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. Metabolism 1975; 24: 665–679
22. Block GA, Swartz RD. Bleeding and hemostatic defects in uremia. Critical care nephrology, C Ronco, R Bellomo. Kluwer Academic, Dordrecht 1998; 783–792
23. Sussman NL, Kelly JH. Extracorporeal liver support and the kidney. Critical care nephrology, C Ronco, R Bellomo. Kluwer Academic, Dordrecht 1998; 959–967
24. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, Schoenhofen M. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23: 81–86
25. Santoro A, Mancini E, Buttiglieri S, Krause A, Yakubovich M, Tetta C. Extracorporeal support of liver function (II part). Int J Artif Organs 2004; 27: 176–185
26. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468–475
27. Boyle M, Kurtovic J, Bihari D, Riordan S, Steiner C. Equipment review: the molecular adsorbents recirculating system (MARS). Crit Care 2004; 8: 280–286
28. Silvester W, Bellomo R, Ronco C. Continuous versus intermittent renal replacement therapy in the critically ill. Critical care nephrology, C Ronco, R Bellomo. Kluwer Academic, Dordrecht 1998; 1225–1228
29. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis cytokines from the circulation of septic patients. Crit Care Med 1993; 21: 522–526
30. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense?. Intensive Care Med 1995; 21: 169–176
31. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol 1995; 116: 62–75
32. Bellomo R, Tipping P, Boyce N. Interleukin-6 and interleukin-8 extraction during continuous venovenous-hemodiafiltration in septic acute renal failure. Ren Fail 1995; 17: 457–466
33. Millar AB, Armstrong L, van der Linden J, Moat N, Ekroth R, Westwick J, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993; 56: 1499–1502
34. Journois D, Pouard P, Greeley WJ, Mauriat P, Vouhe P, Safran D. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 1994; 81: 1181–1189
35. Goldfarb S, Golper TA. Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994; 5: 228–232
36. Ronco C, Tetta C, Lupi A, Galloni E, Bettini MC, Sereni L, et al. Removal for platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995; 23: 99–107
37. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg?. Circ Shock 1992; 38: 145–152
38. Reidy MA, Bowyer DE. Scanning electron microscopy: morphology of aortic endothelium following injury by endotoxin and during subsequent repair. Atherosclerosis 1997; 26: 319–328
39. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433–1440
40. Van Deventer SJH, Bueller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76: 2520–2526
41. Rosenberg RD, Aird WC. Vascular-bed specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555–1564
42. Esmon CT. The protein C pathway. Crit Care Med. (Suppl) 2000; 28: S44–S48
43. Taylor FB, Haddad PA, Hack E, Chang AC, Peer GT, Morrissey JH, et al. Two-stage response to endotoxin infusion into normal human subjects: correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med 2001; 29: 326–334
44. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408–416
45. Pinsky MR. Sepsis: a pro- and anti-inflammatory disequilibrium syndrome. Contrib Nephrol 2001; 132: 354–366
46. Cavaillon JM, Adib-Conquy M, Cloez-Tayarani I, Fitting C. Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: a review. J Endotoxin Res 2001; 7: 85–93
47. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280–287
48. Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991; 173: 1021–1024
49. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481–1486
50. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165–1172
51. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, et al. Role of the intercellular adhesion molecule (ICAM-1) in endotoxin-induced pneumonitis using ICAM-1 anti-sense oligonucleotides, anti-ICAM-1 monoclonal antibodies and ICAM-1 mutant mice. J Clin Invest 1996; 97: 2362–2369
52. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709
53. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, et al. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 4(Suppl): S474–481
54. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 135–143
55. Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky MR, et al. NF-kappa B expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 2000; 162: 1877–1883
56. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock: septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539–1553
57. Marshall JC. Clinical trials of mediator-directed therapy in sepsis: what have we learned?. Intensive Care Med 2000; 26 (Suppl 1) S75–S83
58. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group. JAMA 1997; 277: 1531–1538
59. Fisher CJ, Agosti JM, Opal SM. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697–1702
60. Echtenacher B, Falk W, Mannel D, Krammer PH. Requirement of endogenous tumour necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762–3766
61. van der Meer JWM. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1988; 1: 19–25
62. Silvester W. Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis 1997; 30 (Suppl 4) S38–S43
63. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48: 1563–1570
64. Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA. Complement depletion during haemofiltration with polyacilonitrile membranes. Nephrol Dial Transplant 1996; 11: 117–119
65. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993; 21: 522–526
66. Goldfarb S, Golper TA. Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994; 5: 228–232
67. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26: 1995–2000
68. Braun N, Giolai M, Rosenfeld S, Bamzhaf W, Fretschmer R, Warth H, et al. Clearance of interleukin-6 during continuous veno-venous hemofiltration in patients with septic shock. A prospective, controlled clinical study [abstract]. J Am Soc Nephrol 1993; 4: 336
69. Mariano F, Tetta C, Guida GE, Triolo G, Camussi G. Hemofiltration reduces the priming activity on neutrophil chemiluminescence in septic patients. Kidney Int 2001; 60: 1598–1605
70. Tetta C, Mariano F, Buades J, Ronco C, Wratten ML, Camussi G. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis 1997; 30 (Suppl 4) S57–S65
71. Mariano F, Guida G, Donati D, Tetta C, Cavalli PL, Verzetti G, et al. Production of platelet activating factor in patients with sepsis-associated acute renal failure. Nephrol Dial Transplant 1999; 14: 1150–1157
72. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Haemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997; 23: 878–884
73. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846–853
74. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100–106
75. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23: 288–296
76. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, et al. A pilot study on coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30: 1250–1255
77. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88: 1747–1754
78. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk H D. Mechanism of endotoxin desensitization: involvement of interleukin-10 and transforming growth factor beta. J Exp Med 1995; 181: 1887–1892
79. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 1996; 184: 51–60
80. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies?. Intensive Care Med 1999; 25: 903–910
81. Grootendorst AF, van Bommel EF, van der Hoven B, van Leengoed LA, van Osta AL. High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 1992; 7: 67–75
82. Grootendorst AF, van Bommel EF, van Leengoed LA, van Zanten AR, Huipen HJ, Groeneveld AB. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993; 8: 161–169
83. Grootendorst AF, van Bommel EF, van Leengoed LA, Nabuurs M, Bouman CS, Groeneveld AB. High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock 1994; 2: 72–78
84. Lee PA, Matson JR, Pryor RW, Hinshaw LB. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914–924
85. Rogiers P, Zhang H, Smail N, Pauwels D, Vincent JL. Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999; 27: 1848–1855
86. Yekebas EF, Eisenberger CF, Ohnesorge H, Saalmuller A, Elsner HA, Engelhardt M, et al. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001; 29: 1423–1430
87. Nagashima M, Shin'oka T, Nollert G, Shum-Tim D, Rader CM, Mayer JE, Jr. High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Circulation 1998; 98 (Suppl 19) S378–S384
88. Bellomo R, Kellum JA, Gandhi CR, Pinsky MR. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000; 161: 1429–1436
89. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26–30
90. Journois D, Israel-Biet D, Pouard P, Rolland B, Silvester W, Vouhe P, Safran D. High-volume, zerobalanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996; 85: 965–976
91. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med 1999; 25: 814–821
92. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume hemofiltration in human septic shock. Intensive Care Med 2001; 27: 978–986
93. Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581–3587
94. Lee PA, Weger GW, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1998; 26: 730–737
95. Kline JA, Gordon BE, Williams C, Blumenthal S, Watts JA, Diaz-Buxo J. Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 1999; 27: 588–596
96. Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004; 43: 444–453
97. Morgera S, Haase M, Rocktaschel J, Bohler T, Vargas-Hein O, Melzer C, et al. Intermittent high-permeability hemofiltration modulates inflammatory response in septic patients with multiorgan failure. Nephron Clin Pract 2003; 94: c75–c80
98. Morgera S, Haase M, Rocktaschel J, Bohler T, von Heymann C, Vargas-Hein O, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003; 18: 2570–2576
99. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999; 27: 2096–2104
100. Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, et al. Coupled plasma filtration–adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000; 28: 1526–1533
101. Formica M, Olivieri C, Livigni S, Cesano G, Vallero A, Maio M, Tetta C. Hemodynamic response to coupled plasmafiltration adsorption in human septic shock. Intensive Care Med 2003; 29: 703–708